The diagnostic reagent strip was never meant to be a headline product. It is a piece of paper or plastic, impregnated with chemistry, read by eye or a small reader, and discarded.
Yet by 2026, the strip sits at the intersection of chronic disease management, infectious disease surveillance, and a regulatory landscape that has grown considerably more demanding since the pandemic years. The question now is not whether reagent strips matter, but which strips matter, to whom, and under what rules.
When the Pandemic Ended but the Testing Habit Did Not
-
Previous pandemic antigen cassettes introduced tens of millions of people to the idea that a reliable-ish result could appear on a plastic cassette in ten to fifteen minutes, at home, without a laboratory.
-
That behavioral shift has not fully reversed. Health Canada’s authorization of home-use antigen tests, including self-collection for adults and supervised collection for adolescents, established a regulatory template that other jurisdictions have studied closely.
-
The warnings embedded in those authorizations false negatives in early infection, interference from vitamin C, the importance of reading results within the specified window have become part of the public’s diagnostic literacy.
-
The strip is no longer a mysterious clinical artifact. It is something people argue about at kitchen tables.
Urinalysis Dipsticks and the Silent Chronic Disease Burden
While antigen strips dominated public attention, the quieter workhorse of the reagent strip world remained the multiparameter urinalysis dipstick. The WHO Model List of Essential In Vitro Diagnostics explicitly includes urine dipsticks for albumin, bilirubin, glucose, ketones, and hemoglobin, alongside multi-parameter strips for detecting urinary tract infections. These are not glamorous tests.
They are the tests that catch kidney disease before dialysis, flag uncontrolled diabetes before ketoacidosis, and identify UTIs before sepsis. In health facilities without laboratories which remain the majority in many low- and middle-income settings the dipstick is not a convenience. It is the diagnostic infrastructure.
The Materials Science behind the Test Line
The chemistry inside a reagent strip has quietly advanced. A 2025 study published in Biomedicines described lateral flow immunoassay strips using platinum-decorated poly(2-vinylpyridine) nanoparticles as detection probes for SARS-CoV-2 nucleocapsid protein. In 200 clinical specimens, the strips achieved 74% sensitivity and 100% specificity, with performance superior to conventional lateral flow kits at lower viral loads.
Separately, researchers developed a fluorescence immunochromatographic strip for detecting pepsin in hypopharyngeal saliva as a biomarker for laryngopharyngeal reflux disease, achieving a detection limit of 1.9 ng/mL with no cross-reactivity against pepsinogen I or II. These are not incremental tweaks. They represent a rethinking of what a strip can detect and how sensitively it can do so.
You Can Go Through Our Latest Updated Insights Here: https://www.24lifesciences.com/diagnostic-reagent-strip-market-13344
Saliva, ADA2, and the Expansion of the Biomarker Menu
-
The strip format is also migrating to new sample types and new disease targets. A colloidal gold immunochromatographic strip for adenosine deaminase 2 (ADA2) in saliva successfully confirmed ADA2 deficiency in nine patients with different pathogenic mutations, while 58 of 59 healthy donors tested positive for the enzyme.
-
The test also has potential for diagnosing pleural tuberculosis and identifying head and neck cancer cases.
-
The significance is not just the specific disease. It is the demonstration that a paper-based strip can screen for a rare genetic immunodeficiency using saliva, without venipuncture, without a cold chain, and without a specialist laboratory.
The Regulatory Squeeze: IVDR, CDSCO, and the Chemistry of Compliance
Regulation has become a material input cost. In the European Union, IVDR classification determines whether a reagent strip requires notified body involvement; Class A non-sterile devices may avoid it, but higher-risk categories do not. More subtly, the REACH authorization process for octyl- and nonylphenol ethoxylates surfactants used in some IVD assays has forced reformulation work across product lines, with substitution timelines stretching toward the end of 2027.
In India, CDSCO’s 2026 manufacturing guidance for IVD devices lays out the documentation and validation requirements for domestic strip producers, from analytical sensitivity and cross-reactivity data to clinical performance evidence and post-market surveillance obligations. The strip that costs pennies to manufacture now carries a compliance dossier that can cost far more than the product itself.
The Home-Use Question Nobody Has Fully Answered
-
Home testing is convenient. It is also analytically messier than laboratory testing.
-
The instructions for a typical home antigen test warn that negative results do not exclude infection that samples collected after seven days of symptoms may produce false negatives, and that positive results should be reported to a healthcare provider for public health surveillance. These are not minor caveats.
-
They are the difference between a test that informs clinical decisions and a test that generates noise.
-
As reagent strips expand into home use for chronic conditions urinalysis for diabetes monitoring, for instance the question of who interprets the result, and who acts on it, becomes more urgent.
What the WHO Essential Diagnostics List Tells Us about Priorities?
The WHO EDL is not a market forecast. It is a statement of what countries should be able to procure. Its inclusion of dipsticks for blood typing, clinical chemistry, hematology, and pregnancy testing signals that the global health community considers reagent strips foundational, not optional.
The fourth EDL, published in 2023, expanded to 156 IVD categories, including glucose meter self-monitoring. When a technology appears on the EDL, procurement decisions, donor funding, and national formularies follow. The strip’s presence there is a quiet but durable endorsement.
The Chemistry of Trust
A reagent strip is a promise: that the color change means what it says, that the control line appeared for a reason, that the result is valid for the sample and the moment. That promise is sustained by manufacturing discipline, regulatory oversight, and clinical validation not by the elegance of the format.
In 2026, the diagnostic reagent strip market is not defined by a single blockbuster application. It is defined by the accumulation of small, essential tests that happen outside laboratories, in clinics, homes, and community health posts, where the answer needs to arrive quickly and the cost of being wrong is measured in health outcomes rather than revenue.